Spybiotech seeks clearance in UK to begin clinical testing of SPYVLP-01 for human CMV
Sep. 20, 2023
Spybiotech Ltd. has filed a clinical trial application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate SPYVLP-01, a vaccine targeting human cytomegalovirus (CMV) using its hepatitis B virus-like-particle platform technology.